X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (216) 216
hematology (121) 121
female (110) 110
male (97) 97
adult (96) 96
oncology (85) 85
middle aged (84) 84
index medicus (81) 81
transplantation (58) 58
aged (57) 57
immunology (37) 37
transplantation, autologous (34) 34
animals (31) 31
colony-forming units assay (29) 29
treatment outcome (26) 26
adolescent (25) 25
hematopoietic stem cells - drug effects (25) 25
bone-marrow transplantation (24) 24
cancer (24) 24
hematopoietic stem cell transplantation (24) 24
lymphoma (24) 24
mice (22) 22
progenitor cells (22) 22
chemotherapy (21) 21
stem cells (21) 21
apoptosis (20) 20
medicine, research & experimental (20) 20
bone marrow transplantation (19) 19
cells, cultured (19) 19
lymphomas (19) 19
chronic myelogenous leukemia (18) 18
hematopoietic stem cells - cytology (18) 18
antineoplastic combined chemotherapy protocols - therapeutic use (17) 17
apoptosis - drug effects (17) 17
cell line, tumor (17) 17
peripheral-blood (17) 17
young adult (17) 17
bone marrow - pathology (16) 16
chronic myeloid-leukemia (16) 16
cyclophosphamide - analogs & derivatives (16) 16
hematopoietic stem cells (16) 16
high-dose chemotherapy (16) 16
therapy (16) 16
antineoplastic agents - therapeutic use (14) 14
bone-marrow-transplantation (14) 14
brentuximab vedotin (14) 14
cell division - drug effects (14) 14
disease (14) 14
hematopoietic stem cell transplantation - methods (14) 14
hematopoietic stem cells - pathology (14) 14
mice, scid (14) 14
phase-ii (14) 14
retrospective studies (14) 14
time factors (14) 14
bone-marrow (13) 13
cell biology (13) 13
colony-stimulating factor (13) 13
cyclophosphamide (13) 13
expression (13) 13
hematology, oncology and palliative medicine (13) 13
hodgkin's disease (13) 13
leukemia (13) 13
care and treatment (12) 12
cells (12) 12
flow cytometry (12) 12
follow-up studies (12) 12
growth (12) 12
mafosfamide (12) 12
pregnancy (12) 12
abridged index medicus (11) 11
antigens, cd34 - metabolism (11) 11
cyclophosphamide - administration & dosage (11) 11
cyclophosphamide - pharmacology (11) 11
hematopoietic stem cell mobilization (11) 11
leukemia, myelogenous, chronic, bcr-abl positive - pathology (11) 11
non-hodgkins-lymphoma (11) 11
stem-cells (11) 11
bone marrow cells (10) 10
bone marrow purging (10) 10
combined modality therapy (10) 10
hematologic malignancies (10) 10
hematopoiesis - drug effects (10) 10
hodgkin disease - drug therapy (10) 10
lymphoma, non-hodgkin - therapy (10) 10
recombinant proteins - pharmacology (10) 10
stem cell transplantation (10) 10
transplantation conditioning (10) 10
transplantation, homologous (10) 10
xenograft model antitumor assays (10) 10
activation (9) 9
antigens, cd34 - analysis (9) 9
cell separation (9) 9
disease-free survival (9) 9
dosage and administration (9) 9
drug synergism (9) 9
health aspects (9) 9
hematopoiesis (9) 9
hematopoietic progenitor cells (9) 9
hodgkin disease - pathology (9) 9
leukemia, myeloid, acute - pathology (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 11/2010, Volume 116, Issue 21, pp. 3542 - 3542
Abstract Abstract 3542 Patients affected by Hodgkin's lymphoma (HL) who are chemorecfractory or relapsed after an autologous transplantation (autoSCT) may be... 
Journal Article
Blood, ISSN 0006-4971, 01/2006, Volume 107, Issue 2, pp. 602 - 609
The unfavorable clinical evolution in indolent non-Hodgkin lymphomas suggests defective control of neoplastic growth by the immune system. To address this... 
B-CELLS | METASTATIC MELANOMA | FAS LIGAND | IMMUNE-RESPONSE | APOPTOSIS | CHRONIC LYMPHOCYTIC-LEUKEMIA | TUMOR-CELLS | HEMATOLOGY | PHASE-I | CANCER | PREDICT SURVIVAL
Journal Article
PLoS ONE, ISSN 1932-6203, 04/2013, Volume 8, Issue 4, p. e61603
The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were investigated using a panel of lymphoma cell lines, including... 
FACTOR RECEPTOR INHIBITOR | HEPATOCELLULAR-CARCINOMA | MULTIDISCIPLINARY SCIENCES | DOWN-REGULATION | RAF KINASE | MICROVESSEL DENSITY | REFRACTORY SOLID TUMORS | ANTITUMOR-ACTIVITY | MULTIKINASE INHIBITOR | RAF/MEK/ERK PATHWAY | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Pericytes - drug effects | Apoptosis - drug effects | Cell Count | Humans | Phosphatidylinositol 3-Kinases - metabolism | Extracellular Signal-Regulated MAP Kinases - metabolism | Necrosis | Neovascularization, Pathologic - pathology | Neovascularization, Pathologic - enzymology | Lymphoma - drug therapy | Pericytes - pathology | Angiogenesis Inhibitors - therapeutic use | Lymphoma - enzymology | Lymphoma - pathology | Phosphorylation - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Cell Survival - drug effects | Angiogenesis Inhibitors - pharmacology | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Mice, SCID | Xenograft Model Antitumor Assays | Animals | MAP Kinase Signaling System - drug effects | Neovascularization, Pathologic - drug therapy | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Phenylurea Compounds - pharmacology | Protein Kinase Inhibitors - pharmacology | Niacinamide - pharmacology | Endothelial Cells - pathology | Endothelial Cells - enzymology | Endothelial Cells - drug effects | Antimitotic agents | Non-Hodgkin's lymphomas | Antineoplastic agents | Apoptosis | Cell proliferation | Flow cytometry | Biotechnology | Phosphorylation | Laboratories | Leukemia | Cytotoxicity | Oncology | AKT protein | Kinases | Cancer therapies | Proteins | Liver cancer | Angiogenesis | Pathways | Lymphoid cell lines | Xenografts | Inhibition | Vascular endothelial growth factor | Medical research | Hematology | Tumor cells | Extracellular signal-regulated kinase | MAP kinase | FDA approval | Tumor cell lines | Lymphoma | 1-Phosphatidylinositol 3-kinase | Nodules | Medicine | Cell death | Antiangiogenics | Hypoxia | Lymphomas | Tumors
Journal Article
Leukemia, ISSN 0887-6924, 08/2013, Volume 27, Issue 8, pp. 1677 - 1687
The effects of the Akt inhibitor perifosine and the RAF/MEK/ERK inhibitor sorafenib were investigated using two CD30(+)Hodgkin lymphoma cell lines (L-540 and... 
sorafenib | Akt inhibitors | perifosine | tumor xenografts | Hodgkin lymphoma | necroptosis | MULTIPLE-MYELOMA | MAMMALIAN TARGET | APOPTOSIS | CANCER CELLS | KINASE | TUMOR-CELLS | AKT INHIBITOR | IN-VITRO | ONCOLOGY | DISEASE | LEUKEMIA-CELLS | HEMATOLOGY | Niacinamide - analogs & derivatives | Apoptosis - drug effects | Hodgkin Disease - genetics | Hodgkin Disease - pathology | Gene Expression Profiling | Phosphorylcholine - analogs & derivatives | Phosphorylcholine - administration & dosage | Necrosis | Caspases - metabolism | Phosphorylcholine - pharmacology | Cell Cycle Proteins - genetics | Hodgkin Disease - drug therapy | Gene Expression Regulation, Neoplastic - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Hodgkin Disease - metabolism | Cell Cycle Proteins - metabolism | Antineoplastic Combined Chemotherapy Protocols | Mitochondria - metabolism | Mitochondria - drug effects | Mice, SCID | Niacinamide - administration & dosage | Drug Synergism | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Animals | Mitogen-Activated Protein Kinases - antagonists & inhibitors | Phenylurea Compounds - administration & dosage | Signal Transduction - drug effects | Tumor Burden - drug effects | Cell Line, Tumor | Mice, Inbred NOD | Cell Proliferation - drug effects | Mice | Phenylurea Compounds - pharmacology | Protein Kinase Inhibitors - pharmacology | Niacinamide - pharmacology | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Cluster Analysis | Mitogen-Activated Protein Kinases - metabolism | Cell death | Xenotransplantation | Patient outcomes | Research | Drug therapy, Combination | Drug therapy | Hodgkin's disease
Journal Article
2014, Advances in Experimental Medicine and Biology, Volume 816, 19
Human lymphomas usually develop in specialized tissue microenvironments characterized by different populations of accessory stromal and lymphoid cells that... 
II MIXED CRYOGLOBULINEMIA | REED-STERNBERG CELLS | B-CELL LYMPHOMA | HEPATITIS-C VIRUS | ONCOLOGY | HEPATOCYTE GROWTH-FACTOR | REGULATORY T-CELLS | NON-HODGKINS-LYMPHOMA | TUMOR-ASSOCIATED MACROPHAGES | FOLLICULAR LYMPHOMA | POOR PATIENT SURVIVAL | IMMUNOLOGY
Book Chapter
Clinical Cancer Research, ISSN 1078-0432, 11/2014, Volume 20, Issue 22, pp. 5641 - 5651
Journal Article
European Journal of Cancer Supplements, ISSN 1359-6349, 2010, Volume 8, Issue 7, pp. 171 - 171
Journal Article
Cell Death and Disease, ISSN 2041-4889, 2014, Volume 5, Issue 5, pp. e1265 - e1265
Journal Article
Nature Communications, ISSN 2041-1723, 12/2017, Volume 8, Issue 1, pp. 1 - 14
Journal Article
Journal Article
Blood, ISSN 0006-4971, 03/2017, Volume 129, Issue 10, pp. 1380 - 1388
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 08/2018, Volume 29, Issue 7, pp. 705 - 709
Journal Article